Before taking Vafseo(Vadadustat)

This section highlights critical safety information and monitoring requirements.

Warnings and Monitoring

A Boxed Warning emphasizes an increased risk of death, thrombosis, and major adverse cardiovascular events (MACE). Hemoglobin must be carefully monitored to avoid rapid rises or levels exceeding 11 g/dL. Liver tests (ALT, AST, bilirubin) are required before treatment, monthly for the first 6 months, and as needed. Blood pressure requires monitoring due to risks of worsening hypertension. The drug is contraindicated in patients with uncontrolled hypertension or known hypersensitivity. It is not recommended for patients with active malignancies, cirrhosis, or acute liver disease.